The State of Innovation in Type 2 Diabetes

A Strategic Market and Pipeline Analysis

Last Updated: June 17, 2025

Market Opportunity

2023 Global Market

$57.5B

Current Market Value1

2024-2032 Growth

7.9%

Projected CAGR8

2032 Projection

$76.4B

Expected Market Size8

The Type 2 Diabetes market is undergoing a revolutionary transformation from a focus on glycemic control to comprehensive cardiometabolic care. The market has bifurcated into foundational oral agents and premium therapies offering substantial weight loss and proven cardiovascular/renal benefits. North America leads with 36-41% market share, driven by high disease prevalence and strong uptake of novel therapies.2

T2D Technology Innovation Landscape

This diagram illustrates the key therapeutic mechanisms, delivery approaches, and clinical applications driving innovation in Type 2 Diabetes treatment. Hover over nodes to explore how each approach targets different aspects of the disease pathophysiology.

T2D Therapy Efficacy Landscape

This chart compares the glycemic control (HbA1c reduction) and weight loss efficacy of approved T2D therapeutics. Each point represents a different drug, with positioning showing the trade-offs between glucose lowering and weight management benefits.

Subscribe to our newsletter to see other reports

We'll let you know about new reports

This is only an orientational chart. Gosset provides comprehensive efficacy and safety data from every clinical trial, including detailed adverse event profiles, dosing regimens, and head-to-head comparisons across all timepoints.

Efficacy & Safety Data / Book a Call

Leading Approved T2D Therapeutics

Drug Name (Brand)CompanyMechanism of ActionKey Clinical Trials (NCT)Key PatentsKey Efficacy DataCV/Renal OutcomesPatent Expiration (US)Key DifferentiatorsMarket Position
Tirzepatide (Mounjaro)Eli LillyGLP-1R/GIPR Dual Agonist (Peptide)NCT04255433 (SURPASS-CVOT) Portfolio protection to ~2036HbA1c: -2.1% to -2.6%
Weight: -7.0 to -9.5 kg		SURPASS-CVOT ongoing3~2036First-in-class "twincretin"; superior efficacy vs GLP-1sMarket leader; redefined efficacy standards
Semaglutide (Ozempic/Rybelsus)Novo NordiskGLP-1R Agonist (Peptide/Oral)NCT06409130 (Liver disease), SOUL Trial, FLOW Trial US9764003B2 (exp. 2033) HbA1c: -1.2% to -1.8%
Weight: -4.5 kg		MACE Reduction: 14%
CKD Progression: 24%		~2032First oral GLP-1 (Rybelsus); proven CV benefitsBlockbuster franchise; dual indication
Empagliflozin (Jardiance)BI / Eli LillySGLT2 Inhibitor (Small Molecule)NCT04509674 (EMPACT-MI), NCT03554200EP2981271, WO2020058095A1HbA1c: -0.7% to -0.8%
Weight: -2.2 to -2.5 kg		MACE Reduction: 14%
CV Death: 38%
HHF: 35%		~2025-2026Strong heart failure benefits; renal protectionLeading SGLT2i; broad CV indications
Dapagliflozin (Farxiga)AstraZenecaSGLT2 Inhibitor (Small Molecule)NCT03199053, NCT02725593, NCT00528879 CN03811353.8 (exp. 2023), CN104382859B, EP1506211 (revoked UK) HbA1c: -0.5% to -0.7%
Weight: -2.2 to -3.0 kg		HHF/CV Death: 26%
CKD Progression: 39%		~2025Strong renal outcomes; multiple indicationsEstablished SGLT2i with broad utility
Dulaglutide (Trulicity)Eli LillyGLP-1R Agonist (Peptide)NCT05005741 (vs beinaglutide), NCT03668470 (T1D) US11576950B2 (exp. 2038), WO2019103875A2HbA1c: -0.7% to -1.6%
Weight: -1.4 to -3.0 kg		MACE Reduction: 12%~2027Weekly dosing; proven CV outcomesMature GLP-1; facing competition
Liraglutide (Victoza)Novo NordiskGLP-1R Agonist (Peptide)NCT01272219 (Saxenda), NCT03421119 (biosimilar) KR102417455B1 (CV use, exp. 2037), Generic approved Dec 2024 HbA1c: -0.8% to -1.1%
Weight: -2.1 to -2.5 kg		MACE Reduction: 13%Generic approved Dec 2024First GLP-1 with CV outcomes; daily dosingGeneric competition; legacy asset
Finerenone (Kerendia)BayerNon-steroidal MRA (Small Molecule)NCT01345656 (CHF), NCT01874431 (T2D nephropathy) US9993461 (exp. 2030), US10059707, WO2021074072HbA1c: Minimal
Weight: Neutral		CKD Progression: 18%
CV Composite: 13%		~2029-2035Specialized for T2D+CKD; add-on therapyNiche player in high-risk CKD population
Dorzagliatin (HuaTangNing)Hua MedicineGlucokinase Activator (Small Molecule)NCT03141073 (SEED), NCT03173391 (DAWN), NCT05098470Formulation patent to ~2037, >100 GKA patents portfolioHbA1c: -1.07%
Weight: Neutral		CV/Renal outcomes not yet established~2037 (China)First-in-class GKA; restores glucose sensingChina-approved; novel mechanism

This table covers leading approved therapies. Access comprehensive competitive intelligence on all T2D therapeutics, including regulatory timelines, patent landscapes, and market positioning in Gosset.

Get Market Intelligence / Book a Call

Key T2D Pipeline Programs

Drug NameCompanyTarget/ModalityPhaseKey Trial(s) (NCT)Latest Clinical DataNext MilestoneKey InnovationStrategic Importance
OrforglipronEli LillyOral GLP-1RA (Small Molecule)Phase 3NCT05971940 (ACHIEVE-1) A1C: -1.5% to -1.6%; Weight: -7.9% at 40 wks7T2D regulatory submission expected 2026First effective oral non-peptide GLP-1RACould revolutionize market; oral convenience
RetatrutideEli LillyGGG Triple Agonist (Peptide)Phase 3NCT04881760 (Phase 2), TRIUMPH Program (Phase 3) Phase 2: Weight loss up to 24.2% at 48 wks30Phase 3 data readout 2026-2027Unprecedented weight loss efficacySets new efficacy benchmark for obesity
MazdutideInnovent / Eli LillyGLP-1/GCG Dual Agonist (Peptide)Phase 3NCT05607680 (GLORY-1), NCT06931028 (GLORY-OSA), NCT06884293 (GLORY-3) Weight loss ~15% at 48 wks25China approval expected 2025Strong liver fat reduction; metabolic benefitsMajor player in Asian market
SurvodutideBI / ZealandGLP-1/GCG Dual Agonist (Peptide)Phase 3NCT06077864 (SYNCHRONIZE-CVOT), NCT06352411 (renal impairment) Phase 2: Weight loss up to 14.9% at 46 wks27Phase 3 obesity data expected 2026Dual pathway targeting; CV outcomes trialPotential best-in-class dual agonist
CagriSemaNovo NordiskGLP-1/Amylin Combo (Peptide)Phase 3NCT05567796 (REDEFINE 2), NCT06131437 (vs tirzepatide), NCT06388187Weight loss ~16% at 68 wks29Regulatory submission planned 2026Dual satiety pathway combinationNovo's next-gen obesity therapy
AmycretinNovo NordiskGLP-1/Amylin Co-agonist (Peptide/Oral)Phase 2NCT06064006 (Phase 1b/2a) Weight loss up to 22% at 36 wks (SC)28Phase 3 initiation Q1 2026Unimolecular co-agonist; oral formulationPotential semaglutide successor
CT-388Roche / CarmotGLP-1/GIP Dual Agonist (Peptide)Phase 2NCT04838405 (Phase 1), NCT06628362 (Phase 2 T2D), NCT06525935 (Phase 2 obesity) Phase 1b: Weight loss 18.8% at 24 wks24Phase 2 data expected H2 2025Strong early efficacy data; tirzepatide competitorRoche's re-entry into metabolics
GSBR-1290Structure TherapeuticsOral GLP-1RA (Small Molecule)Phase 2NCT06693843 (Phase 2b obesity) Weight loss 6.2% (placebo-adj.) at 12 wks33Phase 2b T2D trial ongoingDirect competitor to orforglipronValidates oral small molecule approach
NA-931 (BioGlutide™)Biomed IndustriesOral Quadruple Agonist (IGF-1/GLP-1/GIP/GCG)Phase 2NCT06564753 (Phase 2 completed), NCT06732245 (combo w/ tirzepatide) Preclinical: Up to 26% weight loss21Phase 2 data presentation at ADA 2025First quadruple agonist; muscle preservationMost novel multi-target approach

These tables show only a curated selection. Gosset provides access to a comprehensive dataset of over 2,000 T2D assets with detailed clinical, regulatory, and competitive intelligence.

Explore Full Dataset / Book a Call

Key Development Milestones 2025-2027

Q2 2025
Q3 2025
Q4 2025
2026
2027
2028+
Pemvidutide
MASH Phase 2 data (Q2)
Altimmune
NA-931
Phase 2 data at ADA
Biomed Industries
Revita Procedure
REMAIN-1 midpoint data
Fractyl Health
Semaglutide
MASH indication decision
Novo Nordisk
Mazdutide
China approval expected
Innovent/Lilly
CT-388
Phase 2 data readout
Roche
Orforglipron
T2D regulatory submission
Eli Lilly
CagriSema
Regulatory submission
Novo Nordisk
RJVA-001
First-in-human data
Fractyl Health
Retatrutide
Phase 3 TRIUMPH data
Eli Lilly
Multiple Programs
Next-gen approvals
Industry-wide
Market Transformation
Disease modification era
Multiple players
Precision Medicine
Biomarker-guided treatment
Pharma-tech integration

Technology and Innovation Landscape

Multi-Receptor Agonism

  • GLP-1/GIP Dual Agonists: Tirzepatide leads with superior efficacy; multiple competitors emerging3
  • GLP-1/GCG Combinations: Survodutide, mazdutide target enhanced energy expenditure25
  • Triple Agonists: Retatrutide (24% weight loss), targeting GLP-1/GIP/Glucagon receptors30
  • GLP-1/Amylin Combinations: CagriSema showing ~16% weight loss in trials
  • Key innovation: Synergistic effects exceed single-target approaches

Oral Drug Development

  • Small Molecule GLP-1RAs: Orforglipron leads with ~2.1% HbA1c reduction and ~10kg weight loss7
  • Strategic importance: Address injection aversion, expand patient population significantly
  • Key challenges: Balancing peptide-like efficacy with oral tolerability
  • Pipeline: Multiple competitors including GSBR-1290 validating the approach

Digital Health Integration

  • Continuous Glucose Monitoring: Real-time feedback driving behavioral changes and improving outcomes19
  • Digital Therapeutics: FDA-authorized apps like BlueStar® showing ~1.2% HbA1c reductions
  • Digital Twins: Twin Health program achieving 1.8% HbA1c reduction with 89% reaching targets19
  • Closed-Loop Systems: Artificial pancreas technology improving glycemic control

Novel Mechanisms & Gene Therapy

  • Glucokinase Activation: Dorzagliatin approved in China, restores glucose sensing19
  • Mitochondrial Modulation: Imeglimin approved in Japan/India, targets energy metabolism
  • Gene Therapy: GPX-002 reprograms alpha cells to insulin-producing β-like cells62
  • Cell Therapy: Stem cell-derived β-cell replacement showing proof-of-concept cures

Market Paradigm Shift: From Glycemic Control to Organ Protection

The T2D market has undergone a fundamental transformation from glucose-centric to cardiometabolic management:19

  • Value Proposition: MACE reduction and CKD protection now essential for premium pricing
  • Market Bifurcation: Low-cost oral agents vs. high-value organ-protective therapies
  • Clinical Guidelines: SGLT2i and GLP-1RA recommended regardless of HbA1c for CV/renal disease
  • Economic Impact: Higher upfront costs offset by reduced long-term complications
  • Innovation Focus: Beyond glucose control to weight loss, CV benefits, and disease modification

Future Directions & Strategic Imperatives

The next decade will be defined by several key trends and strategic priorities:17

  • Disease Modification: Move from management to remission via β-cell restoration
  • Precision Medicine: Patient subtyping (SIDD, SIRD, MOD, MARD) for targeted therapy
  • Oral Frontier: First effective oral GLP-1RA will reshape market dynamics
  • Multi-Agonism Race: Escalating efficacy competition in weight loss outcomes
  • Digital Integration: Sensor-effector-AI ecosystems becoming standard of care

The Incretin Revolution and "Twincretin" Era

Transforming Treatment Expectations

The success of GLP-1 receptor agonists like semaglutide and dulaglutide fundamentally changed T2D management by demonstrating that therapies could simultaneously address hyperglycemia, obesity, and cardiovascular risk. The 2022 approval of tirzepatide as the first dual GLP-1/GIP receptor agonist marked the beginning of the "twincretin" era, delivering superior efficacy with HbA1c reductions up to 2.6% and weight loss exceeding 9 kg.3

This clinical breakthrough validated the multi-agonist approach and triggered an industry-wide R&D race toward triple and quadruple agonist combinations. Retatrutide's unprecedented 24% weight loss in Phase 2 trials has set a new efficacy benchmark, while oral formulations like orforglipron threaten to democratize access to incretin therapy by eliminating injection barriers.7,30

References

  1. Type 2 Diabetes Mellitus Treatment Market Size, Growth | Industry Trends, 2032. Market Research Future. Available at: https://www.marketresearchfuture.com/reports/type-2-diabetes-mellitus-treatment-market-5669
  2. Type 2 Diabetes Mellitus Treatment Market Report, 2030. Grand View Research. Available at: https://www.grandviewresearch.com/industry-analysis/type-2-diabetes-mellitus-treatment-market-report
  3. FDA approves Mounjaro (tirzepatide) injection to improve glycemic control in adults with type 2 diabetes. May 2022.
  4. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9510507/
  5. New Drug Therapy Approvals 2022. FDA. Available at: https://www.fda.gov/drugs/novel-drug-approvals-fda/new-drug-therapy-approvals-2022
  6. Mounjaro | European Medicines Agency (EMA). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
  7. Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results. Eli Lilly Investors. Available at: https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically
  8. Type 2 Diabetes Market Size to Hit USD 76.39 Billion by 2034. Precedence Research. Available at: https://www.precedenceresearch.com/type-2-diabetes-market
  9. Type 2 Diabetes Market Size to Hit USD 69.55 Billion by 2032. GlobeNewswire. Available at: https://www.globenewswire.com/news-release/2025/04/24/3067455/0/en/Type-2-Diabetes-Market-Size-to-Hit-USD-69-55-Billion-by-2032
  10. Type 2 Diabetes Market size to reach US$ 73.31 Billion by 2032. Coherent Market Insights. Available at: https://www.biospace.com/press-releases/type-2-diabetes-market-size-to-reach-us-73-31-billion-by-2032
  11. Type 2 Diabetes Market Size, Trends and Forecast, 2035. IMARC Group. Available at: https://www.imarcgroup.com/type-2-diabetes-market
  12. Oral Antidiabetic Drugs Market Size & Share Report, 2025-2034. Available at: https://www.gminsights.com/industry-analysis/oral-antidiabetic-drugs-market
  13. North America Type 2 diabetes mellitus treatment Market Size & Outlook, 2030. Grand View Research. Available at: https://www.grandviewresearch.com/horizon/outlook/type-2-diabetes-mellitus-treatment-market/north-america
  14. Type 2 Diabetes Market Report 2025 - Growth And Analysis To 2034. The Business Research Company. Available at: https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report
  15. Type 2 Diabetes Market Trends, Share & Forecast, 2025-2032. Coherent Market Insights. Available at: https://www.coherentmarketinsights.com/industry-reports/type-2-diabetes-market
  16. Diabetes Care Devices Market Growth, Drivers, and Opportunities. MarketsandMarkets. Available at: https://www.marketsandmarkets.com/Market-Reports/diabetes-care-375.html
  17. The Future of the Type 2 Diabetes Market. G-Med. Available at: https://www.g-med.info/post/the-future-of-the-type-2-diabetes-market
  18. Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics. XTalks. Available at: https://xtalks.com/top-15-diabetes-drugs-in-2023-by-2022-sales-statistics-3715/
  19. ADA 2025 Scientific Sessions - Clinical Research Abstracts and Technology Updates
  20. What's Coming in 2022 for Type 2 Diabetes Medications + Technology? Beyond Type 1. Available at: https://beyondtype1.org/2022-type-2-diabetes-treatments/
  21. Biomed Industries Announces Positive Phase 2 Data for NA-931. Available at: https://www.biomedind.com/news-NA-931-Phase2-ADA.html
  22. Lilly announces details of presentations at American Diabetes Association's 85th Scientific Sessions. Available at: https://investor.lilly.com/news-releases/news-release-details/lilly-announces-details-presentations-american-diabetes
  23. Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer? Nasdaq. Available at: https://www.nasdaq.com/articles/novo-nordisks-next-generation-obesity-pipeline-game-changer
  24. Genentech reports positive Phase 1b results for CT-388. May 2024. Available at: https://www.gene.com/media/press-releases/15024/2024-05-15/genentech-reports-positive-phase-ib-resu
  25. Phase 3 Clinical Study of Mazdutide Published in NEJM. PR Newswire. Available at: https://www.prnewswire.com/news-releases/phase-3-clinical-study-of-mazdutide-in-chinese-adults-with-overweight-or-obesity-glory-1-published-in-the-new-england-journal-of-medicine-nejm-302464859.html
  26. Altimmune Announces Initiation of RECLAIM Phase 2 Trial. Available at: https://www.globenewswire.com/news-releases/pemvidutide-reclaim-trial
  27. Survodutide reduces body weight in phase 2 dose-finding trial. PACE-CME. Available at: https://pace-cme.org/news/survodutide-reduces-body-weight-phase-2-dose-finding-trial-overweightobesity/2467319/
  28. Novo Nordisk Announces Top-Line Results for Amycretin. Pharmacy Times. Available at: https://www.pharmacytimes.com/view/novo-nordisk-announces-topline-results-for-amycretin-as-potential-obesity-overweight-treatment
  29. Novo Nordisk's stock drops despite CagriSema hitting Phase III trial goal. Clinical Trials Arena. Available at: https://www.clinicaltrialsarena.com/news/novo-nordisks-stock-drops-despite-cagrisema-hitting-goal-of-phase-iii-trial/
  30. Rapid weight loss in retatrutide trial raises safety concerns despite efficacy. MedPath. Available at: https://trial.medpath.com/news/5b33882561cdc0e7/rapid-weight-loss-in-retatrutide-trial-raises-safety-concerns-despite-efficacy
  31. TRIUMPH 3 retatrutide. BCDiabetes. Available at: https://www.bcdiabetes.ca/handouts/triumph-3-retatrutide
  32. Biomed Industries Expands Patent Protection for Novel Combination Therapy. Available at: https://www.biomedind.com/news-NA-931-patents.html
  33. Structure Therapeutics Reports Positive Phase 2a Data for GSBR-1290. GlobeNewswire. Available at: https://www.globenewswire.com/news-release/2024/06/03/2892147/0/en/structure-therapeutics-reports-positive-topline-data-from-its-phase-2a-obesity-study-and-capsule-to-tablet-pk-study-for-its-oral-non-peptide-small-molecule-glp-1-receptor-agonist-g.html
  34. Structure Therapeutics Reports Positive Topline Data. Available at: https://www.globenewswire.com/news-release/2024/06/03/2892147/0/en/structure-therapeutics-reports-positive-topline-data
  35. Pfizer Discontinues Development of Danuglipron for Chronic Weight Management. Pharmaceutical Executive. Available at: https://www.pharmexec.com/view/pfizer-discontinues-development-danuglipron-chronic-weight-management
  36. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8049051/
  37. Post-Transcriptional Regulation of Immune Responses by RNA-Binding ZFP36 Family Proteins. Frontiers in Immunology. Available at: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.711633/full
  38. ZFP36, an RNA-binding protein promotes hBMSCs osteogenic differentiation. PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/39543732
  39. Hepatocyte Kctd17 inhibition ameliorates glucose intolerance. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9975067/
  40. KCTD17-mediated Ras stabilization promotes hepato. Clinical and Molecular Hepatology. Available at: https://www.e-cmh.org/upload/pdf/cmh-2024-0364.pdf
  41. Kctd17-mediated Chop degradation promotes adipogenic differentiation. ResearchGate. Available at: https://www.researchgate.net/publication/368819362_Kctd17-mediated_Chop_degradation_promotes_adipogenic_differentiation
  42. Trehalose Ameliorates Diabetic Cardiomyopathy: Role of the PK2/PKR Pathway. ResearchGate. Available at: https://www.researchgate.net/publication/357230113_Trehalose_Ameliorates_Diabetic_Cardiomyopathy_Role_of_the_PK2PKR_Pathway
  43. The PKR-T2DM-Apoptosis-Inflammation Axis. European Journal of Dentistry. Available at: https://ejdent.org/index.php/ejdent/article/view/347
  44. Double stranded RNA dependent protein kinase (PKR) and type 2 diabetes. Pediatrics and Perinatology International Journal. Available at: https://medcraveonline.com/PPIJ/double-stranded-rna-dependent-protein-kinase-pkr-and-type-2-diabetes.html
  45. New roles for Prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes. ResearchGate. Available at: https://www.researchgate.net/publication/335369061_New_roles_for_Prokineticin_2_in_feeding_behavior_insulin_resistance_and_type_2_diabetes_studies_in_mice_and_humans
  46. Drug Trials Snapshots: BRENZAVVY. FDA. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-brenzavvy
  47. Finerenone. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8329022/
  48. Finerenone: Potential Clinical Application. MDPI. Available at: https://www.mdpi.com/2077-0383/14/9/3213
  49. Bayer to Share New Data from KERENDIA Clinical Trial Program. Business Wire. Available at: https://www.businesswire.com/news/home/20250603473253/en/Bayer-to-Share-New-Data-from-KERENDIA-finerenone-Clinical-Trial-Program
  50. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients. Diabetes Care. Available at: https://diabetesjournals.org/care/article/44/4/952/138589/Efficacy-and-Safety-of-Imeglimin-Monotherapy
  51. About Us - Hua Medicine. Available at: http://www.yangmay-art.com/En/aboutus
  52. Hua Medicine Announces the Inclusion of Dorzagliatin in the National Reimbursement Drug List. Available at: https://www.huamedicine.com/En/news-231
  53. FDA Approves Generic GLP-1 Medicine For Diabetes Treatment. Powers Health. Available at: https://www.powershealth.org/about-us/newsroom/health-library/2024/12/26/fda-approves-generic-glp-1-medicine-for-diabetes-treatment
  54. bexagliflozin Drug Patent Profile. Drug Central. Available at: https://drugcentral.org/drugcard/5708?q=BEXAGLIFLOZIN
  55. MOUNJARO Drug Patent Profile. Drug Patent Watch. Available at: https://www.drugpatentwatch.com/p/tradename/MOUNJARO
  56. Poxel Announces Grant of New Patent in Japan for Imeglimin. Available at: https://www.poxelpharma.com/en_us/news-media/press-releases/detail/286/poxel-announces-grant-of-new-patent-in-japan-for-the-use-of
  57. Kerendia patent expiration. Pharsight - GreyB. Available at: https://pharsight.greyb.com/drug/kerendia-patent-expiration
  58. Dorzagliatin - Hua Medicine. Available at: https://www.huamedicine.com/En/dorzagliatin
  59. Generic Brenzavvy Availability. Drugs.com. Available at: https://www.drugs.com/availability/generic-brenzavvy.html
  60. Hua Medicine Announces Update on China IP of Dorzagliatin. Available at: https://www.huamedicine.com/En/news-154
  61. Novel Drug Approvals for 2023. FDA. Available at: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
  62. Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates. BioSpace. Available at: https://www.biospace.com/press-releases/fractyl-health-announces-first-quarter-2025-financial-results-and-business-updates
  63. Fractyl Health Advances Rejuva Gene Therapy Platform. Available at: https://ir.fractyl.com/news-releases/news-release-details/fractyl-health-advances-rejuvar-gene-therapy-platform-submission/
  64. Biomed Industries Announces Positive Phase 2 Data for NA-931. Available at: https://www.biomedind.com/news-NA-931-Phase2-ADA.html
  65. Mechanism of Action – Resalis Therapeutics. Available at: https://www.resalistherapeutics.com/science/mechanism-of-action/
  66. Search for clinical trials - EMA - CTIS. Available at: https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-514871-17-00
  67. A Study to Test the Effect of Survodutide (BI 456906). CenterWatch. Available at: https://www.centerwatch.com/clinical-trials/listings/NCT06077864/survodutide-cvot
  68. A Phase 3 Evaluation of cAMP Signaling Biased GLP-1. Diabetes Journals. Available at: https://diabetesjournals.org/diabetes/article/73/Supplement_1/742-P/155871/742-P-A-Phase-3-Evaluation-of-cAMP-Signaling
  69. Innovent Announces Completion of First Participant Dosed in GLORY-OSA. PR Newswire. Available at: https://www.prnewswire.com/news-releases/innovent-announces-completion-of-first-participant-dosed-in-the-seventh-phase-3-clinical-trial-glory-osa-of-mazdutide-in-china-302481798.html
  70. ADA 2025: Novo Nordisk highlights strong portfolio data. GlobeNewswire. Available at: https://www.globenewswire.com/news-release/2025/06/10/3096595/0/en/ADA-2025-Novo-Nordisk-highlights-strong-portfolio-data
  71. 742-P: A Phase 3 Evaluation of cAMP Signaling Biased GLP-1. Available at: https://diabetesjournals.org/diabetes/article/73/Supplement_1/742-P/155871/742-P-A-Phase-3-Evaluation-of-cAMP-Signaling
  72. Press Releases | Wednesday, May 15, 2024 - Genentech. Available at: https://www.gene.com/media/press-releases/15024/2024-05-15/genentech-reports-positive-phase-ib-resu
  73. Orforglipron from Aladdin Scientific. Biocompare. Available at: https://www.biocompare.com/11119-Chemicals-and-Reagents/20928682-Orforglipron/
  74. orforglipron - Drug Hunter. Available at: https://drughunter.com/molecule/orforglipron
  75. CN117903284A - Retatrutide synthesis method - Google Patents. Available at: https://patents.google.com/patent/CN117903284A/en
  76. AU2022298841A1 - Use of mazdutide - Google Patents. Available at: https://patents.google.com/patent/AU2022298841A1/en
  77. Survodutide | C192H289N47O61 | CID 168429725 - PubChem. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Survodutide
  78. Survodutide - Drug Targets, Indications, Patents - Patsnap Synapse. Available at: https://synapse.patsnap.com/drug/9cfad305c16c4c8e87d4fc020706ced6
  79. Novo's Wegovy successor disappoints in second large trial. BioPharma Dive. Available at: https://www.biopharmadive.com/news/novo-nordisk-cagrisema-study-results-diabetes-weight-loss/742008/
  80. ADOCIA Announces Patenting Stable Combinations of GLP-1 and Amylin Analogs. Business Wire. Available at: https://www.businesswire.com/news/home/20241014065229/en/ADOCIA-Announces-Patenting-Stable-Combinations-of-GLP-1-and-Amylin-Analogs
  81. Novo Nordisk ramps up obesity fight, advances amycretin to Phase III. Clinical Trials Arena. Available at: https://www.clinicaltrialsarena.com/news/novo-nordisk-obesity-drug-phase-iii-trial-advance/
  82. Carmot Therapeutics - Genentech. Available at: https://www.gene.com/carmot
  83. Product Development Portfolio - Roche. Available at: https://www.roche.com/solutions/pipeline
  84. US12291530B1 - GLP-1R agonist and therapeutic method thereof - Google Patents. Available at: https://patents.google.com/patent/US12291530B1/en
  85. Aleniglipron - Gasherbrum Bio - AdisInsight. Available at: https://adisinsight.springer.com/drugs/800067725
  86. US12234236B1 - GLP-1R agonist and therapeutic method thereof - Google Patents. Available at: https://patents.google.com/patent/US12234236/en
  87. Pemvidutide - Altimmune - AdisInsight. Available at: https://adisinsight.springer.com/drugs/800037378
  88. Biomed Industries Expands Patent Protection for Novel Combination Therapy. Available at: https://www.biomedind.com/news-NA-931-patents.html
  89. RES-010 - Drug Targets, Indications, Patents - Patsnap Synapse. Available at: https://synapse.patsnap.com/drug/ca6b1a1a24344627907e4860b45bc52b
  90. Resalis Therapeutics Raises €10M in Series A Funding. FinSMEs. Available at: https://www.finsmes.com/2024/01/resalis-therapeutics-raises-e10m-in-series-a-funding.html
  91. FDA Grants Priority Review to Sibeprenlimab for the Kidney Disease IgAN. Managed Healthcare Executive. Available at: https://www.managedhealthcareexecutive.com/view/fda-grants-priority-review-to-sibeprenlimab-for-the-kidney-disease-igan
  92. FDA Accepts NDA for Relacorilant for Endogenous Hypercortisolism. HCPLive. Available at: https://www.hcplive.com/view/fda-accepts-nda-for-relacorilant-for-endogenous-hypercortisolism
  93. Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI. Available at: https://ir.travere.com/press-releases/news-details/2025/Travere-Therapeutics-Announces-FDA-Acceptance-of-sNDA-for-FILSPARI-sparsentan-in-FSGS/default.aspx
  94. Quarterly Drug Pipeline: April 2025. Prime Therapeutics. Available at: https://www.primetherapeutics.com/quarterly-drug-pipeline-april-2025
  95. GLP-1 Pipeline Update: February 2025. Prime Therapeutics. Available at: https://www.primetherapeutics.com/documents/d/primetherapeutics/GLP-1%20Pipeline%20Update%20Table%20Feb%202025

Disclaimer

This is a sample report generated for demonstration purposes only. The information presented should not be used for making financial, investment, or medical decisions. While efforts have been made to ensure accuracy, the data and analysis should be independently verified before any business or clinical use. This report does not constitute financial advice, investment recommendations, or medical guidance.